Cadila Healthcare Ltd

CADILAHC
Health CarePharmaceuticals
MidcapWith a market cap of ₹40,663 cr, stock is ranked 119
Low RiskStock is 1.75x as volatile as Nifty
395.651.55 (-0.39%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹40,663 cr, stock is ranked 119
Low RiskStock is 1.75x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
18.98
PB RatioPB Ratio
2.71
Dividend YieldDiv. Yield
0.88%
Sector PESector PE
36.71
Sector PBSector PB
4.89
Sector Div YldSctr Div Yld
0.70%

Forecast & RatingsDetailed Forecast 

48%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Cadila Healthcare Limited is a pharmaceutical company.

Brands

Cadila

Pharmaceutical company

Zydus Cadila

Investor PresentationView older 

Oct 29, 2021

PDF
View Older Presentations

Brands

Cadila

Pharmaceutical company

Zydus Cadila

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201820192020202112.0213.3714.3715.141.781.851.182.13
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Change in Director(s) 
Announced OnJan 21, 2022

Cadila Healthcare Limited has informed the Exchange regarding Change in Director(s) of the company. | Download

Cadila Healthcare Limited has informed the Exchange regarding Change in Director(s) of the company. | Download

Press Release 
Announced OnJan 20, 2022

Cadila Healthcare Limited has informed the Exchange regarding a press release dated January 20, 2022, titled "Zydus receives final approval from USFDA for Vigabatrin Tablets". | Download

Cadila Healthcare Limited has informed the Exchange regarding a press release dated January 20, 2022, titled "Zydus receives final approval from USFDA for Vigabatrin Tablets". | Download

Cash Dividend 
Ex. DateJul 28, 2021

Final • Div/Share: ₹ 3.5

See all events